Header Logo

Connection

Christopher Goetz to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Dose-Response Relationship, Drug.
Christopher Goetz
Connection Strength
0.542
Dose-Response Relationship, Drug
  1. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
    View in: PubMed
    Score: 0.142
  2. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
    View in: PubMed
    Score: 0.105
  3. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View in: PubMed
    Score: 0.050
  4. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord. 2000 May; 15(3):479-84.
    View in: PubMed
    Score: 0.043
  5. Posthypoxic myoclonus in the rat: natural history, stability, and serotonergic influences. Mov Disord. 2000; 15 Suppl 1:39-46.
    View in: PubMed
    Score: 0.042
  6. Association between antipsychotics and body mass index when treating patients with tics. J Child Adolesc Psychopharmacol. 2010 Aug; 20(4):277-81.
    View in: PubMed
    Score: 0.022
  7. Epidemiology and pathophysiology of tardive dyskinesias. Adv Neurol. 1988; 49:185-97.
    View in: PubMed
    Score: 0.018
  8. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006 Dec; 21(12):2078-81.
    View in: PubMed
    Score: 0.017
  9. The pathophysiology of tardive dyskinesia. J Clin Psychiatry. 1985 Apr; 46(4 Pt 2):38-41.
    View in: PubMed
    Score: 0.015
  10. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol. 2004 Mar-Apr; 27(2):58-62.
    View in: PubMed
    Score: 0.014
  11. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982 Apr; 139(4):494-7.
    View in: PubMed
    Score: 0.012
  12. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol. 2001 Feb; 58(2):249-54.
    View in: PubMed
    Score: 0.011
  13. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000 Mar; 39(3):292-9.
    View in: PubMed
    Score: 0.011
  14. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord. 1999 Nov; 14(6):911-3.
    View in: PubMed
    Score: 0.010
  15. Animal model of posthypoxic myoclonus: effects of serotonergic antagonists. Neurology. 1999 Jan 01; 52(1):16-21.
    View in: PubMed
    Score: 0.010
  16. 5-Hydroxytryptophan-induced myoclonus in guinea pigs: mediation through 5-HT1/2 receptor subtypes. Eur J Pharmacol. 1998 Apr 17; 347(1):51-6.
    View in: PubMed
    Score: 0.009
  17. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology. 1996 Oct; 47(4):1037-42.
    View in: PubMed
    Score: 0.008
  18. Levodopa-induced myoclonus. Arch Neurol. 1975 May; 32(5):330-4.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.